Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

TCR-specific, alpha fetoprotein-enhanced autologous T lymphocytes

A preparation of human autologous T lymphocytes transduced with a viral vector encoding for a T-cell receptor (TCR) specific for human alpha-fetoprotein (AFP), with potential antineoplastic activity. Following administration, the TCR-specific, alpha fetoprotein-enhanced autologous T lymphocytes recognize and bind to AFP antigen-positive cells, which results in lysis and killing of AFP-positive cancer cells. AFP is overexpressed in a variety of cancers.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	AFP-C332 CTLs anti-AFP TCR-expressing autologous CTLs
Abbreviation:	AFP-C332 T cells

TCR-specific, alpha fetoprotein-enhanced autologous T lymphocytes

Search NCI's Drug Dictionary